Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock News

Takeda (TAK) offers a compelling investment case with six late-stage therapies targeting $20 billion in peak sales by 2030-31. TAK's pipeline includes first-in-class and best-in-class candidates, but faces commercialization and competitive risks, especially with high debt levels. Financial restructuring, margin expansion, and debt reduction are critical for TAK's valuation recovery and future d...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE: TAK) today committed JPY 4.6 billion (approx. USD 32.1 million) to four new Global Corporate Social Responsibility (CSR) partners as part of the company's ongoing commitment to building climate-resilient health systems in low- and middle-income countries around the world. Amid rising temperatures and extreme weather even...

High-yield dividend stocks entice investors with payouts two to four times higher than the S&P 500's 1.4% average yield. But high yield often signals trouble -- sluggish growth, stretched payout ratios, or sector headwinds.

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and VELA Transport today announced their business partnership, with Takeda set to become the first biopharmaceutical company to transport its products between Europe and the U.S. using VELA's first-of-its-kind sailing cargo trimaran. VELA designed and will operate a fleet of new generation sailing cargo vessels, powere...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that Rhonda Pacheco, most recently group vice president of U.S. Cardiometabolic Health at Eli Lilly, will join Takeda, effective September 29, as president of Takeda's U.S. Business Unit and will be a member of the Takeda Executive Team. Pacheco will succeed Julie Kim, who was appointed by the Takeda Board of Director...

Takeda Pharmaceutical Company Limited (NYSE:TAK ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 3:20 PM EDT Company Participants Milano Furuta - CFO & Director Conference Call Participants Shinichiro Muraoka - Morgan Stanley, Research Division Presentation Shinichiro Muraoka Equity Analyst Okay. So let's start the session with Takeda.

Takeda Pharmaceutical Company Limited (NYSE:TAK ) Oveporexton (TAK-861) Investor Call on Phase 3 Narcolepsy Type 1 Data Presented at World Sleep 2025 Company Participants Christopher David O'Reilly - Global Head of Investor Relations & Global Finance Andrew Plump - President of Research & Development and Representative Director Sarah Sheikh Heather Dean Julie Kim - President of the U.S. Busines...

SINGAPORE & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861)1, a potential first-in-class investigational oral orexin receptor 2 (OX2R)-selective agonist in narcolepsy type 1 (NT1), during multiple oral presentations at the World Sleep 2025 Congress in Singapor...